20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Cogent Biosciences Inc (COGT) operates in the BIOTECHNOLOGY industry and is headquartered in Waltham, United States with about 258 employees. Its market capitalization is roughly $5 billion. In the fiscal year ended 2025-12-31, COGT reported $0M in revenue and ($329M) in net income.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | — | $0M | $0M | $0M | $0M | $0M | $8M | $22M | $10M | $8M | $6M | $3M |
| Gross Profit | — | ($5M) | ($4M) | ($4M) | ($6M) | $0M | ($18M) | $22M | $10M | $8M | $6M | $3M |
| Gross Margin % | — | — | — | — | — | — | -227.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($389M) | ($333M) | ($276M) | ($208M) | ($148M) | ($76M) | ($82M) | ($32M) | ($36M) | ($26M) | ($19M) | ($7M) |
| Operating Margin % | — | — | — | — | — | — | -1044.3% | -143.0% | -369.9% | -312.8% | -300.1% | -220.8% |
| Net Income | ($377M) | ($329M) | ($256M) | ($192M) | ($133M) | ($72M) | ($75M) | ($30M) | ($35M) | ($25M) | ($18M) | ($7M) |
| Net Margin % | — | — | — | — | — | — | -950.4% | -134.5% | -354.8% | -304.9% | -285.2% | -220.8% |
| EBITDA | ($373M) | ($321M) | ($252M) | ($189M) | ($142M) | ($70M) | ($35M) | ($31M) | ($35M) | ($25M) | ($18M) | ($6M) |
| Earnings Per Share (EPS) | $-2.35 | $-2.04 | $-2.32 | $-2.42 | $-2.26 | $-1.87 | $-6.75 | $-3.97 | $-5.55 | $-3.45 | $-2.45 | $-0.89 |
| Shares Outstanding (M) | 171M | 161M | 110M | 80M | 59M | 39M | 11M | 8M | 6M | 7M | 7M | 7M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | — | $0M | $0M | $0M | $0M | $0M | $4M | $0M |
| Gross Profit | — | ($1M) | ($1M) | — | ($1M) | ($1M) | $2M | ($1M) |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($103M) | ($104M) | ($99M) | ($83M) | ($76M) | ($75M) | ($74M) | ($75M) |
| Operating Margin % | — | — | — | — | — | — | -1717.9% | — |
| Net Income | ($96M) | ($97M) | ($102M) | ($81M) | ($74M) | ($72M) | ($68M) | ($71M) |
| Net Margin % | — | — | — | — | — | — | -1582.6% | — |
| EBITDA | ($94M) | ($95M) | ($105M) | ($79M) | ($72M) | ($71M) | ($67M) | ($70M) |
| Earnings Per Share (EPS) | $-0.56 | $-0.57 | $-0.64 | $-0.58 | $-0.64 | $-0.64 | $-0.61 | $-0.64 |
| Shares Outstanding (M) | 171M | 171M | 161M | 140M | 114M | 113M | 110M | 110M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($308M) | ($264M) | ($208M) | ($154M) | ($119M) | ($59M) | ($36M) | ($42M) | ($32M) | ($26M) | ($19M) | $18M |
| Capital Expenditures (CapEx) | $2M | $2M | $1M | $3M | $7M | $2M | $0M | $0M | $1M | $1M | $3M | $2M |
| Free Cash Flow (FCF) | ($309M) | ($266M) | ($208M) | ($156M) | ($126M) | ($60M) | ($36M) | ($42M) | ($33M) | ($27M) | ($22M) | $16M |
| FCF Margin % | — | — | — | — | — | — | -459.5% | -184.7% | -339.4% | -319.9% | -345.4% | 526.5% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($77M) | ($87M) | ($79M) | ($64M) | ($55M) | ($67M) | ($61M) | ($52M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $0M | $0M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($78M) | ($87M) | ($80M) | ($64M) | ($55M) | ($67M) | ($61M) | ($52M) |
| FCF Margin % | — | — | — | — | — | — | -1413.1% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $835M | $938M | $328M | $313M | $301M | $232M | $251M | $49M | $86M | $49M | $76M | $95M |
| Cash & Cash Equivalents | $181M | $312M | $98M | $53M | $140M | $220M | $242M | $37M | $56M | $28M | $41M | $90M |
| Total Liabilities | $302M | $301M | $72M | $56M | $45M | $18M | $16M | $18M | $26M | $21M | $23M | $25M |
| Total Debt (Short + Long-Term) | $1M | $224M | $2M | $1M | $1M | $2M | $2M | $2M | $4M | $3M | $1M | $0M |
| Total Shareholders' Equity | $532M | $636M | $256M | $258M | $256M | $214M | $235M | $32M | $60M | $28M | $52M | $70M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive COGT viewer.
About TickerBase · Data methodology & sources · Privacy · Terms